Duration of tonic immobility in chickens as a function of alpha-adrenergic receptor stimulation and blockade

Central depressant effects and toxicity of propofol in chicks

Propofol is an ultra-short acting anesthetic agent. The information on the pharmacological and toxicological effects of propofol in the chicken is rather limited. This study examines the toxicity and pharmaco-behavioral effects of propofol given intraperitoneally in 7–10 day-old chicks. The median effective doses of propofol for the induction of sedation, analgesia to electric stimulation and sleep in the chicks were 1.82, 2.21 and 5.71 mg/kg, respectively. The 24-h median lethal dose of propofol in chicks was 57.22 mg/kg. The therapeutic indices of propofol for sedation, analgesia and sleep were 31.4, 25.9 and 10, respectively. Propofol at 0.5 and 1 mg/kg reduced the locomotor activity and increased the duration of tonic immobility in chicks. Propofol at 2 and 4 mg/kg caused analgesia to electric stimulation as well as analgesia and anti-inflammatory responses against formalin test in chicks. Propofol at 5, 10 and 20 mg/kg induced sleep in chicks for 8.4 to 25 min. Physostigmine shortened the sleep duration of propofol. Data suggest that propofol induces anti-inflammatory action and central nervous system depression in chicks resulting in sedation, analgesia and anesthesia with wide safety margin. These effects could form the basis of further pharmacological and toxicological studies on propofol in the young chick model, and the drug could be safely applied clinically in the chicken.

Developmental and behavioral effects of medetomidine following in ovo injection in chicks

Developmental and behavioral effects of medetomidine were assessed in chicks following in ovo exposure on incubation day 4. Medetomidine at 25 and 50 μg/egg injected once into the air cell on incubation day 4, dose-dependently decreased the number of viable chick embryos starting on day 10 of the incubation. The percentages of successful hatching in the control and medetomidine treated groups were 93, 60 and 47%, respectively. Embryo lethalities in these groups were 7, 40 and 53%, respectively. In ovo exposure of the chicks to medetomidine at 25 and 50 μg/egg did not significantly affect the body weight of the chicks as well as their morphometric measurements. In another experiment, 3- and 8-day old chicks exposed to medetomidine in ovo (25 μg/egg) were monitored in the open-field for 5 min. Medetomidine suppressed the open-field activity of both 3- and 8-day old chicks. This was manifested by a significant increase in the latency to move from the central square of the open-field arena and a decrease in the number of lines crossed (ambulation) with an additional decrease in vocalizations of the 3-day old chicks when compared with respective age-matched control values. In the same medetomidine-exposed chicks the duration of tonic immobility significantly increased in comparison with respective control values. Pharmacological challenge of the medetomidine-exposed chicks (8-day old) with medetomidine at 25 μg/kg, intramuscularly significantly increased the latencies to onset of sedation and loss of righting reflex and decreased the duration of sleep when compared with the saline-control group challenged in the same manner. The data suggest that medetomidine could be a behavioral teratogen in chicks following in ovo exposure.

Metoclopramide-induced central nervous system depression in the chicken

Background

Metoclopramide is a dopamine D2-receptor antagonist used as an antiemetic and gastroprokinetic agent in man and animals. The drug causes sedation as a side effect in man. Such a sedative action of metoclopramide has not been documented in the chicken as the drug is not used clinically in this species. The present study examines the central nervous system depressant effects of metoclopramide in 7–14 days old broiler chicks.

Results

Injection of metoclopramide at 50, 100 and 200 mg/kg, subcutaneously (s.c.) induced sedation in the chicks in a dose dependent manner. The chicks manifested, within 3.6–19 minutes of metoclopramide injection, signs of sedation characterized by drooping of the head and wings, closed eyelids, reduced motility and decreased distress calls. The duration of sedation ranged between 37.2 to 163.4 minutes. Metoclopramide at 100 and 200 mg/kg induced, within 12.2 and 6.2 minutes, sleep (loss of righting reflex) for 43.8 and 158.6 minutes, respectively. The median effective doses of metoclopramide for induction of sedation and sleep in the chicks were 11 and 53 mg/kg, s.c., respectively. Lower doses of metoclopramide (5 and 10 mg/kg, s.c.) significantly decreased the open-field activity of the chicks and increased the durations of their tonic immobility. All treated-chicks recovered from the central nervous system depressant effect of metoclopramide without any observable adverse effects.

Conclusion

The data suggest that metoclopramide induces central nervous system depression in chicks, and the drug could have potential clinical applications as a sedative-hypnotic agent in avian species not intended for human consumptions.

Tonic immobility in guinea pigs: a behavioural response for detecting an anxiolytic-like effect?

Tonic immobility (TI) is considered to be an innate fear response characterized by a temporary state of profound and reversible motor inhibition. TI occurs in a wide range of species in a predator-prey confrontation and is hypothesized to be a terminal defence response occurring when there is physical contact between prey and predator. The objective of the present study was to investigate the validity of the TI model in guinea pigs for detection of anxiolytic and/or antidepressant drug activity. Compounds that reduced TI include the serotonin (5-HT) releaser fenfluramine, the 5-HT(1A) receptor agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and buspirone, the 5-HT(2C/2B) receptor antagonist SB206553, the 5-HT(2A) receptor antagonist MDL 100.151 -- but only at doses thought also to inhibit 5-HT(2C) receptors--the noradrenaline (NA) reuptake inhibitor desipramine, the benzodiazepine inverse agonist FG-7142, the alpha(2)-adrenergic receptor antagonist yohimbine, the neurokinin (NK)(1) receptor antagonist L-733.060, and the NK(2) receptor antagonist SR-48968. Compounds that increased TI include the benzodiazepine agonists diazepam and alprazolam, and the alpha(2)-adrenergic receptor agonist clonidine. The selective 5-HT reuptake inhibitors citalopram, paroxetine and fluoxetine, the 5-HT(1A) receptor antagonist WAY100.635, the 5-HT(2C) receptor agonist MK-212, the 5-HT/NA reuptake inhibitor imipramine, the NA reuptake inhibitor talopram, the benzodiazepine antagonist flumazenil, the alpha(2)-adrenergic receptor antagonist idazoxan and the psychostimulant amphetamine did not have any effect. These findings indicate that the serotonergic, noradrenergic and neurokinin systems are involved in mediating or modulating TI behaviour in guinea pigs. The potential of TI as a behaviour for detecting anxiolytic-like effect may be questioned due to the contradictory effect of the benzodiazepine ligands, which may be attributed to the sedative and/or ataxic effects of the compounds. Nevertheless, there is preclinical evidence suggesting that 5-HT(1A) receptor agonists, 5-HT(2C) receptor antagonists and NK(1) and NK(2) receptor antagonists possess anxiolytic potential. Only when results of clinical investigations of the anxiolytic potential of non-benzodiazepine ligands (for example the NK receptor antagonists) are available, will it be possible to determine fully the predictive validity of the TI model.

Receptor binding in Japanese quail selected for long or short tonic immobility

Japanese quail, selectively bred for long (LTI) and short (STI) tonic immobility (TI) responses, are thought to represent high and low fear groups, respectively. To study the neurochemical mechanisms underlying the behavioral distinctions, binding parameters were determined at the benzodiazepine, 5-HT1A, 5-HT3, alpha 2, and opioid receptor sites in the forebrains of the two lines. No differences were found in 5-HT1A, 5-HT3, alpha 2, mu- or kappa-opioid receptor binding between the lines. The KD for the binding of [3H]-flunitrazepam at the benzodiazepine receptor was significantly greater in the LTI than in the STI birds, indicating lower affinity for benzodiazepine ligands. The lines did not differ in benzodiazepine receptor number. Using [3H]-naltrindole, the LTI line was found to have fewer delta-opioid receptors than the STI line; the birds did not vary with respect to the affinity of these receptors. Thus, the selective breeding of the two lines has resulted in differences in benzodiazepine and delta-opioid binding, and these could produce differences in activity levels, fear, and pain responses, all of which could contribute to the tonic immobility response.

Differential cholinergic influences on the immobility response in various strains of domestic fowl

A series of five experiments examined the effects of two anticholinergic drugs, atropine and scopolamine, on the duration of tonic immobility (TI) and susceptibility to the TI response in both Production Red and White Leghorn chickens (Gallus gallus), in an attempt to resolve previous contradictory findings about the effects of cholinergic manipulations on tonic immobility. These two anticholinergic drugs significantly reduced the duration of TI and, therefore, supported the conclusion that cholinergic systems are involved with the immobility response. However, the effects of these drugs on TI differed depending on the age, strain, local population, and handling experience of the individual birds.

Immobilization and restraint effects on pain reactions in animals

Acute physical restraint represents a potent stressor in several animal species and is accompanied by a complex pattern of hormonal responses and functional changes in the central nervous system. Repeated immobilization leads to partial blunting of the behavioral and hormonal responses, with transient modifications of neurotransmitter systems in the brain. Pain reactions, as investigated by different kinds of nociceptive tests, are usually attenuated both during and immediately following acute immobilization and the analgesic effect of opiate compounds potentiated; these behavioral alterations may be attributed at least in part to activation of an endogenous opioid system. In some species, restraint may induce a reflex immobility (animal hypnosis or tonic immobility) which is also characterized by suppression of pain reactions in rabbits, probably subserved by different mechanisms. Analysis of available data suggests that pain testing in unanesthetized, restrained animals may involve alterations of the animal's reactivity to noxious stimuli.

Central and peripheral effects of serotonin on the immobility response in chickens

The effects of low and high doses of serotonin on tonic immobility (TI) duration and susceptibility in 10- and 45-day-old chickens were examined. High doses of serotonin reduced the number of inductions required to produce TI, regardless of the subject's age. In contrast, low and high doses of serotonin produced biphasic increases and decreases in TI duration in 10-day-old birds, but there were no apparent effects on immobility duration by either dose of this drug in older chickens. These results are discussed in terms of the formation of the blood-brain barrier in domestic fowl and the differential peripheral versus central actions by serotonin on TI susceptibility and response duration.

Animal pharmacology of guanfacine

The pharmacologic data obtained from animal experiments with guanfacine, a novel, centrally acting antihypertensive agent, are reviewed. When given orally, guanfacine lowers systemic blood pressure in conscious DOCA-NaCl-hypertensive rats, Grollman rats and spontaneously hypertensive rats in a dose-dependent manner. It is also effective in renal hypertensive cats. Guanfacine reduces blood pressure in cats, rabbits and rats after injection into the lateral cerebral ventricle and in dogs after infusion into the vertebral artery at intravenously ineffective doses. Vagally mediated reflex bradycardia in dogs is enhanced. The preganglionic splanchnic (sympathetic) nerve activity is reduced in cats. In rats, guanfacine reduces the noradrenaline turnover in the brain stem. All these findings indicate a central site of action. Peripheral alpha-adrenoceptor stimulant properties of guanfacine have been demonstrated in various studies. In addition to postsynaptic stimulant effects, presynaptic guanfacine-induced inhibition of sympathetic heart nerve stimulation is antagonized by rauwolscine but not by prazosin, indicating a highly preferential alpha 2-agonistic presynaptic action of the drug. In receptor binding studies using rat cortex membranes and human platelets, guanfacine exhibited a high selectivity for alpha 2 adrenoceptors. Guanfacine has the advantage over other centrally acting antihypertensives of being less sedative and causing no rebound hypertension after discontinuation of treatment. The latter is mainly due to its pharmaco-kinetic properties.

P-chlorophenylalanine attenuates tonic immobility duration in chickens

The results of two experiments demonstrated a dose-dependent reduction in tonic immobility (TI) duration by p-chlorophenylalanine (PCPA) in White Leghorn cockerels. In Experiment 1, five-day old chicks were given five intraperitoneal injections of either saline or 75 or 150 mg/kg of PCPA at a rate of one injection a day for five days. The effects of these injections were evaluated one day after the last injection. A total of 750 mg/kg of PCPA significantly reduced TI duration but 375 mg/kg did not. In Experiment 2, chicks were given either two saline injections, two 375 mg/kg PCPA injections, or one 375 mg/kg PCPA injection and one saline injection. The effects of these injections were evaluated either one or three days after injections. A total of 750 mg/kg of PCPA significantly reduced TI both one and three days after injections but 375 mg/kg of PCPA did not. Previous failures to obtain significant PCPA effects on TI may reflect insufficient drug amounts.